Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patients

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  2015-07-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00280-015-2820-xPMID 26198314
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials.

  2015cited by this paper
• Optimizing Oncology Therapeutics Through Quantitative Translational and Clinical Pharmacology: Challenges and Opportunities

  2015cited by this paper
• Progression-free survival: helpful biomarker or clinically meaningless end point?

  2015cited by this paper
• Evaluation of Tumor Size Response Metrics to Predict Survival in Oncology Clinical Trials

  2014cited by this paper
• Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial.

  2013influential reference
• Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer.

  2013cited by this paper
• Application of tumor measurement-based metrics in the real world.

  2013cited by this paper
• Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.

  2013cited by this paper
• Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration

  2013influential reference
• Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma.

  2012cited by this paper
• Estimation of renal cell carcinoma treatment effects from disease progression modeling

  2012cited by this paper
• Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth

  2012cited by this paper
• Dynamic tumor modeling of the dose–response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial

  2012cited by this paper
• Erratum: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial (Lancet (2011) 378 (1931-39))

  2012cited by this paper
• Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

  2011cited by this paper
• A Modeling and Simulation Framework to Support Early Clinical Drug Development Decisions in Oncology

  2011cited by this paper
• Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.

  2011cited by this paper
• Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy

  2010cited by this paper
• Elucidation of Relationship Between Tumor Size and Survival in Non‐Small‐Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development

  2009cited by this paper
• Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.

  2009cited by this paper
• Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

  2009cited by this paper
• Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

  2007cited by this paper
• Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.

  2007cited by this paper
• Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

  2007cited by this paper
• Sunitinib in patients with metastatic renal cell carcinoma.

  2006cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• [New guidelines to evaluate the response to treatment in solid tumors].

  2000cited by this paper
• Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

  1999influential reference
• A new look at the statistical model identification

  1974cited by this paper

• Future Directions for Quantitative Systems Pharmacology.

  2025cites this paper
• Application of Machine Learning for Predicting Progression‐Free and Overall Survival in Patients With Renal Cell Carcinoma

  2025cites this paper
• Model-Informed Dose Optimization of Pazopanib in Real-World Patients with Cancer

  2025cites this paper
• Predicting survival in prospective clinical trials using weakly-supervised QSP

  2025cites this paper
• Bridging the gap between two‐stage and joint models: The case of tumor growth inhibition and overall survival models

  2024cites this paper
• Mechanistic Learning for Predicting Survival Outcomes in Head and Neck Squamous Cell Carcinoma

  2024cites this paper
• Integrated modeling of biomarkers, survival and safety in clinical oncology drug development.

  2024cites this paper
• Tumor growth and overall survival modeling to support decision making in phase Ib/II trials: A comparison of the joint and two‐stage approaches

  2024cites this paper
• Tumor growth inhibition‐overall survival modeling in non‐small cell lung cancer: A case study from GEMSTONE‐302

  2023cites this paper
• Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition‐Survival Modeling Framework

  2023cites this paper
• Bayesian forecasting of tumor size metrics and overall survival

  2022cites this paper
• Early response dynamics predict treatment failure in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with cetuximab and nivolumab.

  2022cites this paper
• Tumor growth inhibition modeling of individual lesion dynamics and interorgan variability in HER2‐negative breast cancer patients treated with docetaxel

  2021cites this paper
• Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition–overall survival modeling framework

  2021cites this paper
• The search for surrogacy in patient derived xenograft mouse trials: glass is less than half full

  2020cites this paper
• Tumor Size and Overall Survival in Patients With Platinum-Resistant Ovarian Cancer Treated With Chemotherapy and Bevacizumab

  2019cites this paper
• Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models

  2019cites this paper
• A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors

  2019cites this paper
• TumorEncode - Deep Convolutional Autoencoder for Computed Tomography Tumor Treatment Assessment

  2018cites this paper
• Role of Clinical Pharmacodynamics Studies in the Era of Precision Medicines Against Cancer

  2018cites this paper
• Population Modeling of Tumor Kinetics and Overall Survival to Identify Prognostic and Predictive Biomarkers of Efficacy for Durvalumab in Patients With Urothelial Carcinoma

  2018cites this paper
• A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients

  2017influential citation
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 243 Pharmacometrics to improve clinical benefit assessment in oncology

  2017cites this paper
• Array of translational systems pharmacodynamic models of anti-cancer drugs

  2016cites this paper
• Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline

  2016cites this paper
• Prognostic Significance of Early Tumor Shrinkage Under Second-Line Targeted Therapy for Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Study in Japan

  2016cites this paper
• Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.

  2016cites this paper
• Pharmacometric Models for Antibody Drug Conjugates and Taxanes in HER2+ and HER2- Breast Cancer

  2016cites this paper